医药生物行业跨市场周报：呼吸道疾病进入高发期，关注产业链投资机会

Investment Rating - The report maintains a "Buy" rating for companies such as Tai Chi Group, Yuyue Medical, and Qianhong Pharmaceutical, while recommending "Hold" for companies like Hengrui Medicine and Tiantan Biological [3][10]. Core Viewpoints - The report highlights the rising incidence of respiratory diseases, suggesting investment opportunities in the related industry chain, particularly in testing, vaccines, cold medicines, and anti-infection drugs [2][24][46]. Summary by Sections Market Review - The A-share pharmaceutical and biotechnology index fell by 1.91%, underperforming the CSI 300 index by 3.27 percentage points, ranking 23rd among 31 sub-industries [1][39]. - The H-share Hang Seng Healthcare Index rose by 0.48%, lagging behind the Hang Seng Index by 1.78 percentage points [1][13]. Industry Research - The report indicates a sustained increase in acute respiratory infectious diseases, with varying trends among different pathogens. The overall positivity rate for influenza viruses has risen by 6.3% compared to the previous week [21][46]. - It recommends focusing on companies involved in testing (e.g., Yingtong, Shengxiang Biological), vaccines (e.g., Hualan Biological, Gendik), cold medicines (e.g., China Resources Sanjiu, Jichuan Pharmaceutical), and anti-infection drugs (e.g., Fuan Pharmaceutical, Dongya Pharmaceutical) [2][24]. Company Announcements and R&D Updates - Recent clinical applications include Shenzhou Cell's SCTB14 injection and Yifang Biological's D-2570 tablet, both newly undertaken [49]. - The report tracks ongoing clinical trials for various drugs, including Zhenhua Tianqing's AL2846 and Ganli Pharmaceutical's Bofang Glucagon, which are in Phase III trials [49]. Financial Performance and Market Trends - The basic medical insurance revenue for the first ten months of 2024 is reported at 2,306.5 billion yuan [30]. - The report notes a slight year-on-year increase of 0.1% in the pharmaceutical manufacturing industry's revenue for the first ten months of 2024 [66].